ID: ALA4170674

Max Phase: Preclinical

Molecular Formula: C31H33N3O5

Molecular Weight: 527.62

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc(Nc2cc(OC(C)c3cccc(C(=O)NCc4ccc(C)cc4)c3)ccn2)cc(OC)c1OC

Standard InChI:  InChI=1S/C31H33N3O5/c1-20-9-11-22(12-10-20)19-33-31(35)24-8-6-7-23(15-24)21(2)39-26-13-14-32-29(18-26)34-25-16-27(36-3)30(38-5)28(17-25)37-4/h6-18,21H,19H2,1-5H3,(H,32,34)(H,33,35)

Standard InChI Key:  KQHUWBDVXBZPFA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 527.62

Molecular Weight (Monoisotopic): 527.2420

AlogP: 6.23

#Rotatable Bonds: 11

Polar Surface Area: 90.94

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 7.02

CX LogP: 5.61

CX LogD: 5.47

Aromatic Rings: 4

Heavy Atoms: 39

QED Weighted: 0.24

Np Likeness Score: -1.00

References

1. Tian Y, Zhang T, Long L, Li Z, Wan S, Wang G, Yu Y, Hou J, Wu X, Zhang J..  (2018)  Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.,  143  [PMID:29174814] [10.1016/j.ejmech.2017.11.002]

Source

Source(1):

• Scientific Literature